Micah Benson
Company: KSQ Therapeautics
Job title: Chief Scientific Officer
Seminars:
Chair’s Opening Remarks 8:55 am
day: Post-Conference Day - Tackling Solid Tumors
Engineering TIL to Thrive in Hard-to-Treat Solid Tumors Using CRISPR/Cas9 Gene Editing 1:00 pm
Harnessing the advantages of polyclonal TIL products to elicit anti-tumor responses Rational design of engineered TIL, or eTIL, boosts anti-tumor potency and persistence eTIL may improve the overall patient experience with TIL therapyRead more
day: Post-Conference Day - Tackling Solid Tumors